Hanyu Medical IPO, leading product ValveClamp reshapes TMV market pattern
Hanyu Medical has been listed and heard on the Hong Kong Stock Exchange. The company is a medical technology company mainly dedicated to R&D, production and sales of interventional cardiac devices.
China's mitral “unicorn” begins countdown to listing to explore the core logic of long-term ownership of Hanyu Healthcare
The Zhitong Finance App learned that on September 13, Hanyu Medical, a leader in the field of structural heart disease interventional treatment in China, published a collection of post-hearing materials, which meant that Hanyu Medical began the countdown to its listing. When Hanyu Medical comes to market, investors need to explore the company's deep investment value from the perspective of major product pipelines, strong R&D capabilities, and business prospects from behind its strong technology development capabilities. TMVR is taking the lead in treatment and raising industry entry barriers Hanyu Medical, founded in 2016, is committed to the development and commercialization of innovative medical devices in the field of structural heart disease. It is the first batch of development in China
Hanyu Medical passed the Hong Kong Stock Exchange hearing. Yunfeng Fund is a shareholder and focuses on medical devices in the field of structural heart disease
Recently, according to the Hong Kong Stock Exchange, Shanghai Hanyu Medical Technology Co., Ltd. passed the Hong Kong Stock Exchange listing hearing, and CICC and Citi are its co-sponsors. According to public information, Hanyu Medical was founded in 2016 and is a medical device R&D and commercialization enterprise focusing on structural heart diseases. Meanwhile, in 2019, Hanyu Medical established a subsidiary, Xinyu Pet Medicine, to expand its business into the field of interventional medical devices for pets. Hanyu Medical's core product is ValveCLAMP, which is mainly suitable for treating primary and secondary mitral valve repair surgery for mitral valve reflux disease. According to the prospectus, this property
Yunfeng Fund invests in shares, cardiac medical device vendor Hanyu Medical passes Hong Kong stock listing hearing | IPO News
Mitral valve repair (TMVR) cardiac medical device vendor Shanghai Hanyu Medical Technology Co., Ltd. (Hanyu Medical for short) recently passed the Hong Kong Stock Exchange listing hearing. CICC and Citigroup are the company's joint sponsors. According to the prospectus of an innovative medical device developer in the heart field, Hanyu Medical, established in 2016, is a domestic platform-based innovative medical device R&D and industrialization enterprise. The company is committed to the development and commercialization of innovative medical devices in the field of structural heart disease, with a particular focus on China's mitral valve intervention (TMV) market (which can be subdivided into mitral valve replacement (TMVR) and mitral valve repair (TMVR))
Hanyu Medical passed the Hong Kong Stock Exchange listing hearing. V-clamp, a mitral valve reflux interventional device, leverages the emerging blue ocean
Hanyu Medical heard through the Hong Kong Stock Exchange how blockbuster products clamped into the hundreds of billions of mitral valve treatment market.
Hanyu Medical was founded in 2016 and has completed six rounds of financing from 2017 to March 2021. Investors include Yunfeng Fund, Oriental Securities, CITIC Industrial Fund, Zhejiang Merchants Innovation Capital and other institutions.
Less than 5 years after its establishment, the heart medical device manufacturer aims at the high-growth blue ocean market.
Author | Guosheng process Editor | Xiaobai "is about to break the monopoly of foreign companies on mitral valve repair equipment." In April this year, Shanghai Hanyu Medical filed a prospectus on the Hong Kong Stock Exchange, which was launched on September 13 after the hearing. The company is a leader in the field of structural heart disease devices in China. Although structural heart disease is rarely heard of, many people are no stranger to mitral regurgitation. This is the most common structural heart disease, with an incidence of 10.6 million cases in China. What is mitral regurgitation? The heart has a total of four valves, of which the mitral valve is an one-way valve connecting the left atrium and the left ventricle.
Hanyu Medical is hearing about the rapid rise of new domestic innovative medical device stars
On September 13, 2021, Hanyu Medical's prospectus went online after being heard by the Hong Kong Stock Exchange.
Through the hearing, Hanyu Medical will compete in the global blue ocean with “structural mind+electrophysiology+pet mind”
Interpretation of New shares? "structural Valve + Electrophysiology" two wings fly together in the field of mitral valve in China. Unicorn medical treatment listed in Hong Kong.
If 2019 is the year of the explosion of biotechnology listing on the Hong Kong Stock Exchange, then 2021 is a new era of medical devices. According to wind data, three intrusive medical device companies have listed in Hong Kong since July, which also makes the Hong Kong stock market immersed in the performance period feel a small wave of intrusive medical devices. In addition, Hanyu Medical also hung up the prospectus after the hearing on September 13 to increase the popularity of intrusive medical devices. Zhitong Financial APP learned that Hanyu Medical is a medical technology company that mainly focuses on the field of structural heart disease, and its products mainly cover valve repair and other hearts.
New stock news | Hanyu Medical Co., Ltd. focuses on medical devices in the field of structural heart disease through the hearing of the Hong Kong Stock Exchange.
According to the Hong Kong Stock Exchange, Shanghai Hanyu Medical Technology Co., Ltd. (Shanghai Hanyu Medical Technology Co., Ltd.) China International Capital Corporation and Citigroup are co-sponsors through the listing hearing of the HKEx. Shanghai Hanyu Medical Technology Co., Ltd. is a medical device company dedicated to the research, development and commercialization of innovative medical devices in the field of structural heart disease, with a particular focus on the transcatheter mitral valve (TMV) market in China. According to Frost Sullivan, the company's core products
According to Hong Kong Stock Exchange documents, Shanghai Hanyu Medical Technology Co., Ltd. - B passed the Hong Kong Stock Exchange listing hearing.
According to Hong Kong Stock Exchange documents, Shanghai Hanyu Medical Technology Co., Ltd. - B passed the Hong Kong Stock Exchange listing hearing.
An inventory of valvular diseases blocks the dream of human longevity. How can innovative therapeutic instruments break the curse?
Editor's note: the mitral valve field has been hot in the past two years. In the primary market, there has been a sharp rise in valuation and competition for projects in the mitral valve field. In the secondary market, the field of mitral interventional therapy has attracted more than 4 billion yuan. Recently, Academician GE Junbo published "Valvular Disease is a hurdle that must be overcome in human longevity", clarifying the relationship between valvular disease and human longevity, and pointing out that minimally invasive interventional therapy is the inevitable way to treat valvular disease. On the basis of Academician GE Junbo's article, Arterial Network combs the mitral valve field and takes stock of the leading domestic enterprises and products for readers. Academician GE Junbo: valvular disease is essential for human longevity.
"forgotten valve" ushered in the next "beat"?
Hanyu Medical delivery Table Hong Kong Stock Exchange, what is the interest of this high-end heart device player?
Recently, Hanyu Medical Technology, a high-end heart device company, submitted an application for listing on the Hong Kong Stock Exchange, with China International Capital Corporation and Citigroup as joint sponsors. It is worth noting that Hanyu Medical, which delivered the form on the Hong Kong Stock Exchange, signed a listing counseling agreement with China International Capital Corporation in December last year, intending to list in Science and Technology Innovation Board and laying out the "Amusement" structure at the same time. So what is the qualification of this innovative medical device company? Hanyu Medical: a pioneer in the field of transcatheter mitral valve repair in China from the global market, with the development of interventional surgery, structural heart disease devices have gradually become a high-growth, large-volume, high-value growth track. According to marke
Hanyu Medical listed in Hong Kong: planning to invest in Yunfeng Fund of BABA
Source: unicorn knew editor for a long time. Arti this article is for information exchange only and does not constitute any transaction proposal. Hanyu Medical is a medical technology company dedicated to the research, development and commercialization of innovative medical devices in the field of structural heart disease, and has a leading position in China's transcatheter mitral valve (TMV) market. According to Frost Sullivan, the company's core product, ValveClamp, is expected to become the first domestically developed TMV device, as well as the world's first heart-to-heart edge-to-edge TMV repair (TMVr) device. According to market information, Hanyu Medical completed An in 2017.
New stock news | Hanyu Medical delivery form the main board of the Hong Kong Stock Exchange. It is expected that the core product ValveClamp will be registered and listed in Q1 in 2023.
According to the disclosure of the Hong Kong Stock Exchange on April 14, Shanghai Hanyu Medical Technology Co., Ltd. submitted an application for listing on the main board of the Hong Kong Stock Exchange, with China International Capital Corporation and Citigroup as its co-sponsors, Zhitong Financial APP learned. Hanyu Medical is a medical technology company dedicated to the research, development and commercialization of innovative medical devices in the field of structural heart disease, and has a leading position in China's transcatheter mitral valve (TMV) market. According to Frost Sullivan, the company's core product, ValveClamp, is expected to become the first domestically developed TMV device, as well as the world's first upcoming heart-to-heart edge-to-edge TMV repair (T
Shanghai Hanyu Medical Technology applies for Hong Kong IPO
Shanghai Hanyu Medical Technology submitted pre-listing documents to Hong Kong Exchanges and Clearing, and CICC and Citigroup were co-sponsors of the offering.
Hanyu Medical completed 500 million yuan D+ round financing BABA's Yunfeng fund led the investment.
DoNews3 news (Zhai Jiru) on the 16th, Hanyu Medical, which focuses on the development of medical products in the cardiovascular field, has completed 500 million yuan of D+ round financing, led by BABA's Yunfeng Fund, and followed by Jiangsu Ruihua, Octagon Capital, Yi Fangda, leading Capital, former shareholder Honghui Capital and other institutions. It is understood that Hanyu Medical leads the country in the development of interventional medical devices for cardiac valvular disease, and its independently developed mitral interventional device ValveClamp has the characteristics of convenient operation, less trauma, large capture range and so on. The product was completed in October 2018.
Hanyu Medical completed 500 million yuan D+ round financing, and Yunfeng Fund led the investment.
On March 15, Shanghai Hanyu Medical Technology Co., Ltd. officially announced the completion of nearly 500 million yuan D+ round financing. This round of financing is led by Yunfeng Fund, followed by Jiangsu Ruihua, Octagon Capital, Yi Fangda, leading Capital, original shareholder Honghui Capital and other institutions. On March 15, Shanghai Hanyu Medical Technology Co., Ltd. officially announced the completion of nearly 500 million yuan D+ round financing. This round of financing is led by Yunfeng Fund, followed by Jiangsu Ruihua, Octagon Capital, Yi Fangda, leading Capital, original shareholder Honghui Capital and other institutions. Hanyu Medical was founded in 2016.
No Data